# Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

> **NCT05723991** · PHASE4 · UNKNOWN · sponsor: **Chunguang yang (101937)** · enrollment: 36 (estimated)

## Conditions studied

- Radical Cystectomy
- Urothelial Carcinoma

## Interventions

- **DRUG:** Disitamab Vedotin and Gemcitabine

## Key facts

- **NCT ID:** NCT05723991
- **Lead sponsor:** Chunguang yang (101937)
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-28
- **Primary completion:** 2024-09-28
- **Final completion:** 2025-09-28
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05723991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05723991, "Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05723991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*